NEW YORK (GenomeWeb) – Tempus announced today that it has partnered with the University of Chicago Medicine on a project to improve personalized care for breast cancer patients.
Under the terms of the deal, Tempus will conduct molecular sequencing for about 1,000 breast cancer patients receiving treatment at the school, then analyze the data to generate additional genomic data for a subset of the patients. That information will be used by the University of Chicago Medicine to discover novel genomics patterns that can help determine which patients will respond to particular therapies.
Additional terms were not disclosed.
"We are excited to partner with Tempus on this initiative and eager to support its efforts to build the largest clinically annotated molecular data set in breast cancer," University of Chicago researcher Olufunmilayo Olopade, who is working directly with Tempus under the collaboration, said in a statement. "This could improve clinical care and lead to novel research opportunities."
Tempus has recently inked a number of sequencing deals with hospitals and research institutions including Duke University, the University of Michigan, and the Mayo Clinic.